Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems

Prediction of Human Pharmacokinetics in 2013 and Beyond

J. Brian Houston
Drug Metabolism and Disposition December 2013, 41 (12) 1973-1974; DOI: https://doi.org/10.1124/dmd.113.055376
J. Brian Houston
Centre for Applied Pharmacokinetic Research, Manchester Pharmacy School, University of Manchester, Manchester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The utility of in vitro generated kinetic data to provide quantitative prediction of in vivo pharmacokinetic behavior is well established and forms a cornerstone of many research projects in drug metabolism and disposition, particularly within the pharmaceutical industry. This issue provides several excellent examples of the use of in vitro techniques for prediction of human pharmacokinetics (PK). The general area of in vitro–in vivo extrapolation (IVIVE) is broad and hence the spectrum of topics covers various aspects drug clearance and distribution and drug-drug interactions. Some articles were commissioned whereas others were identified during the reviewing process. Overall they provide a snapshot of activity at the end of 2013. They document that whereas the translation of some in vitro approaches is now established, other areas are in their infancy and need more development.

Prediction of metabolic clearance is an example of a mature in vitro–in vivo extrapolation (IVIVE) area. Di et al. (2013a) provide here an overview of best practices and illustrate a wide application. The area is dominated by examples of hepatic cytochrome P450 (P450), but application beyond P450 enzymes to UDP-glucuronosyltransferases (UGTs) and aldehyde oxidase are now evident. Clearance prediction, and IVIVE in general, is increasingly coupled with physiologically based pharmacokinetic (PBPK) models to allow prediction not limited to specific parameters but to generate a time course that can further inform quantitative aspects of drug absorption, distribution, metabolism, and excretion processes (as outlined here by Shardlow et al., 2013). The dynamic rather than static approaches with a time dimension rather than a time-averaged estimate results in far more comprehensive usage of the in vitro data. An excellent example is contained in this issue (Xu et al., 2013), where the importance of CYP2B6 polymorphisms is explored in defining efavirenz clearance.

Prediction of transporter hepatic clearance is an area of great interest and contrasts markedly with the state of play for metabolic hepatic clearance. The complexity of this is becoming evident when delineating the interrelationships between not only enzymes and transporters but also between uptake and efflux transporters and between transporters and passive processes acknowledged (Parker and Houston, 2008; Yabe et al., 2011; Jones et al., 2012; Menochet et al., 2012). It would appear that multiple in vitro models are required, and to integrate these different sources of data requires PBPK modeling procedures. This and other aspects of best practices for transporter-related parameter estimations and predictions have been collated by the International Transporter Consortium (Zamek-Gliszczynski et al., 2013).

The balance of active and passive processes in membrane transport of drugs is often helped by consideration of the Biopharmaceutical Drug Disposition Classification System (BDDCS) (Wu and Benet, 2005). Here Kikuchi et al. (2013) review the evidence for the utility of the BDDCS in predicting brain penetration from in vitro–derived P-gp efflux ratios.

A limitation of standard in vitro methodologies for obtaining drug clearance, whether metabolic or transporter-mediated, is the relatively short lifetime of enzymes in the in vitro incubation. The particularly short time of microsomal incubations is one of several reasons why hepatocytes have become more widely employed. However, even hepatocytes in traditional culture (suspension or monolayer) can only be useful for a few hours. The need to measure the metabolic clearance of low turnover drugs is becoming increasingly important with the design of new drugs that do not use the well characterized enzymes P450 and UDP-glucuronosyltransferases. Hence the articles by Di et al. (2013b) and Chan et al. (2013), concerned with evaluating novel approaches to hepatocyte incubation that provide increased longevity for hepatocyte incubations, should be of great interest to many.

The importance of the gut to clearance of certain drugs and also drug-drug interactions (DDIs) has been appreciated for some time. However the most useful way of building this in with liver has received limited attention. Karlsson et al. (2013) provide a useful analysis of the current position in this area.

Prediction of metabolic DDI has also been an IVIVE area that has been extensively studied. This has benefitted particularly from the use of PBPK and the availability of commercial software. We now appreciate the potential of metabolites’ contributions to metabolic DDI and here Callegari et al. (2013) provide a retrospective analysis of this complexity. Fueled by the regulatory adoption of MIST (Metabolites in Safety Testing) (Smith and Obach, 2010), this has become routinely investigated. Ways in which we can adapt existing models to include metabolites for parent drug perpetrators are explored here by Lutz et al. (2013).

Enzyme (particularly P450) induction as a DDI mechanism for increased clearance has received much attention. In contrast other mechanisms for increased clearance, such as activation (for example through CYP3A4 allosteric effects), are less studied and regarded by many as purely an in vitro phenomenon. Blobaum et al. (2013) provide an interesting case example for in vivo relevance using a rat model, which will lend itself to wider use to explore the wider application of this potential player in DDIs.

Beyond 2013 there is little doubt that the in vitro kinetics of transporters and the factors controlling intracellular drug concentrations will continue to be a major focus for achieving successful in vivo human prediction. Clearer understanding and maturation of approaches, both experimental and modeling, together with integration into the existing metabolic clearance and DDI strategies, will be achieved to keep pace with the drugs of the future. As the in vitro toolbox continues to expand and PBPK models are refined, our ability to make valuable in vivo predictions of complex events from comparatively simple in vitro experiments will continue to grow and provide a holistic view of the processes involved in drug metabolism and disposition.

Footnotes

    • Received October 11, 2013.
    • Accepted October 11, 2013.
  • dx.doi.org/10.1124/dmd.113.055376.

Abbreviations

DDI
drug-drug interaction
IVIVE
in vitro–in vivo extrapolation
P450
cytochrome P450
PBPK
physiologically based pharmacokinetic
  • Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    Blobaum AL, Bridges TM, Byers FW, Turlington M, Mattmann M, Morrison RD, Mackie J,Lavreysen H, Bartolome JM, MacDonald GJ, et al. (2013) Hetertropic activity of P450 3A by a positive allosteric modulator of metabotrophic glutamate receptor 5: In vitro to in vivo translation and potential impact on clinicality relevant drug-drug interactions. Drug Metab Dispos 41:2066–2075.
  2. ↵
    1. Callegari E,
    2. Kalgutkar AS,
    3. Leung LY,
    4. Obach RS,
    5. Plowchalk DR, and
    6. Tse S
    (2013) Drug metabolites as cytochrome P450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development. Drug Metab Dispos 41:2047–2055.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Chan T,
    2. Yu H,
    3. Moore A,
    4. Khetani S, and
    5. Tweedie DJ
    (2013) Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos 41:2024–2032.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Di L,
    2. Feng B,
    3. Goosen TC,
    4. Lai Y,
    5. Steyn SJ,
    6. Varma MV, and
    7. Obach RS
    (2013a) A perspective on the prediction of drug disposition attributes in drug research and development. Drug Metab Dispos 41:1975–1993.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Di L,
    2. Atkinson K,
    3. Orozco CC,
    4. Funk C,
    5. Zhang H,
    6. McDonald TS,
    7. Tan B,
    8. Lin J,
    9. Chang C, and
    10. Obach RS
    (2013b) In vitro-in vivo correlation for low clearance compounds using hepatocyte relay met. Drug Metab Dispos 41:2018–2023.
    OpenUrlAbstract/FREE Full Text
    1. Frederick CB and
    2. Obach RS
    (2012) Metabolites in Safety Testing: “MIST” for the clinical pharmacologist. Clin Pharmacol Therap 87:345–350.
    OpenUrl
  6. ↵
    1. Jones HM,
    2. Barton HA,
    3. Lai YA,
    4. Bi YA,
    5. Kimoto E,
    6. Kempshall S,
    7. Tate SC,
    8. El-Kattan A,
    9. Houston JB,
    10. Galetin A,
    11. et al.
    (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007–1017.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Karlsson FH, Bouchene S, Hilgendorf C, Dolgos H, and Peters SA (2013) Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and development. Drug Metab Dispos 41:2033–2046.
  8. ↵
    1. Kikuchi R,
    2. de Morais SM, and
    3. Kalvass JC
    (2013) In vitro P-gp efflux ratio can predict the in vivo brain penetration regardless of BDDCS class. Drug Metab Dispos 41:2012–2017.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Lutz JD,
    2. Vandenbrink BM,
    3. Babu NK,
    4. Nelson WL,
    5. Kunze KL, and
    6. Isoherranen N
    (2013) Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for prediction of multiple time-dependent inhibitor systems. Drug Metab Dispos 41:2056–2065.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Ménochet K,
    2. Kenworthy KE,
    3. Houston JB, and
    4. Galetin A
    (2012) Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther 341:2–15.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Parker AJ and
    2. Houston JB
    (2008) Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. Drug Metab Dispos 36:1375–1384.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Shardlow C,
    2. Generaux G,
    3. Patel A,
    4. Tai G,
    5. Tran T, and
    6. Bloomer J
    (2013) Impact of physiologically-based pharmacokinetic modelling and simulation in drug development. Drug Metab Dispos 41:1994–2003.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Wu CY and
    2. Benet LZ
    (2005) Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11–23.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Xu C,
    2. Quinney SK,
    3. Guo Y,
    4. Hall SD,
    5. Yi L, and
    6. Desta Z
    (2013) CYP2B6 pharmacogenetics-based in vitro-in-vivo extrapolation (VIVE) of efavirenz clearance by PBPK modelling. Drug Metab Dispos 41:2004–2011.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Yabe Y,
    2. Galetin A, and
    3. Houston JB
    (2011) Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 39:1808–1814.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Zamek-Gliszczynski MJ,
    2. Lee CA,
    3. Poirer A,
    4. Benzt J,
    5. Ellens H,
    6. Ishikawa T,
    7. Jamei M,
    8. Kalvass JC,
    9. Nagar S,
    10. Pang KS,
    11. et al.
    (2013) ITC recommendations for transporter kinetic parameter estimation and translational modelling of transport-mediated PK and DDIs in humans. Nature 94: 64–79.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 41 (12)
Drug Metabolism and Disposition
Vol. 41, Issue 12
1 Dec 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prediction of Human Pharmacokinetics in 2013 and Beyond
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems

In Vitro–In Vivo Prediction

J. Brian Houston
Drug Metabolism and Disposition December 1, 2013, 41 (12) 1973-1974; DOI: https://doi.org/10.1124/dmd.113.055376

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems

In Vitro–In Vivo Prediction

J. Brian Houston
Drug Metabolism and Disposition December 1, 2013, 41 (12) 1973-1974; DOI: https://doi.org/10.1124/dmd.113.055376
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Footnotes
    • Abbreviations
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Clearance Prediction Using HepatoPac
  • In Vitro–In Vivo Correlation of P-gp Efflux Ratio
  • Heterotropic Activation of CYP3A by a Novel mGlu5 PAM
Show more Special Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics